Tekla Enterprise Value Over E B I T D A from 2010 to 2024

HQH Stock  USD 17.08  0.89  4.95%   
Tekla Healthcare's Enterprise Value Over EBITDA is increasing with slightly volatile movements from year to year. Enterprise Value Over EBITDA is estimated to finish at 16.48 this year. For the period between 2010 and 2024, Tekla Healthcare, Enterprise Value Over EBITDA quarterly trend regression had mean deviation of  5.32 and range of 21.9829. View All Fundamentals
 
Enterprise Value Over EBITDA  
First Reported
2010-12-31
Previous Quarter
15.69
Current Value
16.48
Quarterly Volatility
6.71822929
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tekla Healthcare financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tekla Healthcare's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Interest Expense of 0.0 or Selling General Administrative of 2.5 M, as well as many indicators such as Price To Sales Ratio of 14.45, Dividend Yield of 0.0246 or PTB Ratio of 0.58. Tekla financial statements analysis is a perfect complement when working with Tekla Healthcare Valuation or Volatility modules.
  
Check out the analysis of Tekla Healthcare Correlation against competitors.

Latest Tekla Healthcare's Enterprise Value Over E B I T D A Growth Pattern

Below is the plot of the Enterprise Value Over E B I T D A of Tekla Healthcare Investors over the last few years. It is Tekla Healthcare's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tekla Healthcare's overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Over E B I T D A10 Years Trend
Slightly volatile
   Enterprise Value Over E B I T D A   
       Timeline  

Tekla Enterprise Value Over E B I T D A Regression Statistics

Arithmetic Mean6.85
Geometric Mean6.86
Coefficient Of Variation98.09
Mean Deviation5.32
Median7.11
Standard Deviation6.72
Sample Variance45.13
Range21.9829
R-Value0.36
Mean Square Error42.19
R-Squared0.13
Significance0.18
Slope0.55
Total Sum of Squares631.88

Tekla Enterprise Value Over E B I T D A History

2024 16.48
2023 15.69
2022 13.65
2021 -4.34
2020 7.11
2019 3.73
2018 -5.5

About Tekla Healthcare Financial Statements

Investors use fundamental indicators, such as Tekla Healthcare's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Tekla Healthcare's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Enterprise Value Over EBITDA 15.69  16.48 

Currently Active Assets on Macroaxis

When determining whether Tekla Healthcare Inv offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tekla Healthcare's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tekla Healthcare Investors Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tekla Healthcare Investors Stock:
Check out the analysis of Tekla Healthcare Correlation against competitors.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Healthcare. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.145
Dividend Share
1.66
Earnings Share
1.31
Revenue Per Share
0.197
Quarterly Revenue Growth
(0.06)
The market value of Tekla Healthcare Inv is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Tekla Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Healthcare's market value can be influenced by many factors that don't directly affect Tekla Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.